Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

1.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

PMID:
12149456
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.

Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH.

Hematol Oncol. 2009 Dec;27(4):190-7. doi: 10.1002/hon.894.

PMID:
19274615
[PubMed - indexed for MEDLINE]
3.

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Clin Cancer Res. 2006 Dec 15;12(24):7374-9.

PMID:
17189410
[PubMed - indexed for MEDLINE]
Free Article
4.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL.

Science. 2001 Aug 3;293(5531):876-80. Epub 2001 Jun 21.

PMID:
11423618
[PubMed - indexed for MEDLINE]
Free Article
5.

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW.

Mini Rev Med Chem. 2004 Mar;4(3):285-99. Review.

PMID:
15032675
[PubMed - indexed for MEDLINE]
6.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Barthe C, Gharbi MJ, Lagarde V, Chollet C, Cony-Makhoul P, Reiffers J, Goldman JM, Melo JV, Mahon FX.

Br J Haematol. 2002 Oct;119(1):109-11.

PMID:
12358910
[PubMed - indexed for MEDLINE]
7.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

PMID:
15256422
[PubMed - indexed for MEDLINE]
Free Article
8.

Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.

Chien JH, Tang JL, Chen RL, Li CC, Lee CP.

Leuk Res. 2008 Nov;32(11):1724-34. doi: 10.1016/j.leukres.2008.04.023. Epub 2008 Jul 7.

PMID:
18603297
[PubMed - indexed for MEDLINE]
9.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ.

Curr Opin Hematol. 2004 Jan;11(1):35-43. Review.

PMID:
14676625
[PubMed - indexed for MEDLINE]
10.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
[PubMed - indexed for MEDLINE]
11.

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL.

Cancer Cell. 2002 Aug;2(2):117-25.

PMID:
12204532
[PubMed - indexed for MEDLINE]
Free Article
12.

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Azam M, Latek RR, Daley GQ.

Cell. 2003 Mar 21;112(6):831-43.

PMID:
12654249
[PubMed - indexed for MEDLINE]
Free Article
13.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

PMID:
17317816
[PubMed - indexed for MEDLINE]
Free Article
14.

[Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].

Mayer J.

Vnitr Lek. 2002 Jan;48(1):45-9. Czech.

PMID:
11852587
[PubMed - indexed for MEDLINE]
15.

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.

Tanaka R, Kimura S.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1387-98. doi: 10.1586/14737140.8.9.1387. Review.

PMID:
18759691
[PubMed - indexed for MEDLINE]
16.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.

Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.

PMID:
18223278
[PubMed - indexed for MEDLINE]
Free Article
17.

[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].

Ouyang Z, DU QF, Liu XL, Zhang S, Zhu HQ, Gong JM, Song LL, Ouyang LY, Liu Z.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):704-6. Chinese.

PMID:
18504184
[PubMed - indexed for MEDLINE]
Free Article
18.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

PMID:
19240172
[PubMed - indexed for MEDLINE]
Free Article
19.

[The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].

Miyanishi S, Umeki K, Hayashi T, Fukutsuka K, Okumura A, Kishimori C.

Rinsho Byori. 2003 Oct;51(10):1023-9. Japanese.

PMID:
14653203
[PubMed - indexed for MEDLINE]
20.

Roots of imatinib resistance: a question of self-renewal?

Burchert A.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):152-61. Epub 2007 Aug 1. Review.

PMID:
17683977
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk